First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Opens in a new tab or window In this phase Ib/II trial, 45 patients were initially enrolled who received enfortumab vedotin ...

muscle-invasive bladder cancer who had undergone bladder-removal surgery to receive adjuvant therapy with pembrolizumab every ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 ...

Advanced bladder cancer has a poor prognosis compared to ... efficacy and safety of enfortumab vedotin in combination with pembrolizumab in patients with previously untreated unresectable locally ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

At ESMO, oncologists got their first look at the results of the EV-302/KEYNOTE-A39 trial of MSD’s PD-1 inhibitor Keytruda (pembrolizumab ... with metastatic bladder cancer,” said Dr Apolo ...

ALPMF's expanding lineup of cancer drugs, including zolbetuximab, positions them for substantial market growth and potential appreciation.

Keytruda (pembrolizumab) is a prescription drug ... ve already tried chemotherapy and at least one other therapy. Bladder cancer: Keytruda is prescribed to adults to treat bladder cancer that ...

Bladder cancer refers to the growth of a tumor within ... an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of ...

Data suggest that cabozantinib and pembrolizumab can be effective in patients with advanced gastric or gastroesophageal junction cancer whose disease is resistant or refractory to immune checkpoint ...

In the current trial, researchers investigated whether the immune checkpoint inhibitor pembrolizumab would also be effective as an adjuvant treatment. They randomly assigned 702 patients with ...